Johnson & Johnson's potential blockbuster therapy receives FDA approval for market launch

According to the Smart Finance APP, Johnson & Johnson (JNJ.US) announced that the FDA has approved its antibody therapy Imaavy (nipocalimab) for the treatment of generalized myasthenia gravis (gMG) in adults and children 12 years and older who are positive for anti-AChR and anti-MuSK antibodies. According to the press release, this therapy is the first neonatal Fc receptor (FcRn) blocker approved for this patient population.